Drug Trial Radar · NCT05552326
A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia
Last checked: Nov 20, 2026Latest source record: Oct 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
446
Actual
Start
Aug 31, 2022
Primary completion
Dec 17, 2024
Study completion Sep 12, 2025
Sponsor
- Lead sponsor
- Ionis Pharmaceuticals, Inc.Ionis Pharmaceuticals (IONS)
- Sponsor type
- Industry
- First posted
- Sep 23, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy of olezarsen as compared to placebo on the percent change in fasting triglycerides (TG) from baseline.
Conditions
- Severe Hypertriglyceridemia
Interventions
OlezarsenDrug
Olezarsen will be administered by SC injection.
PlaceboDrug
Olezarsen-matching placebo will be administered by SC injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change from Baseline in Fasting TG Compared to PlaceboTime frame: Baseline and Month 6
Locations
205 sites in 23 countries. Site status is shown where the registry gives one.
Central Research Associates, Inc.
Birmingham, Alabama
Alabama Clinical Therapeutics, LLC Alabaster
Birmingham, Alabama
Onyx Clinical Research
Peoria, Arizona
NRC Research Institute
Los Angeles, California
Accel Research Sites
DeLand, Florida
Finlay Medical Research
Greenacres City, Florida
University of Florida Jacksonville
Jacksonville, Florida
Meridien Research
Maitland, Florida
Columbus Clinical Services
Miami, Florida
Harmony Clinical Research, Inc
North Miami Beach, Florida
Combined Research Orlando Phase I-IV
Orlando, Florida
3Sync Research
Sunrise, Florida
R & B Medical Center LLC
Tampa, Florida
JSV Clinical Research Study, Inc.
Tampa, Florida
Metabolic Research Institute
West Palm Beach, Florida
Emory University
Atlanta, Georgia
Accel Clinical Research
Eatonton, Georgia
Northeast Georgia Medical Center
Gainesville, Georgia
Randomize Now
Newnan, Georgia
St. Vincent Medical Group
Carmel, Indiana
University of Kansas Medical Center (KUMC)
Kansas City, Kansas
The Research Group of Lexington, LLC
Lexington, Kentucky
University of Louisville
Louisville, Kentucky
Louisville Metabolic and Atherosclerosis Research Center (L-MARC)
Louisville, Kentucky
Grace Research, LLC
Bossier City, Louisiana
Clinical Trials of America LA, LLC
Monroe, Louisiana
University of Maryland School of Medicine
Baltimore, Maryland
Maryland Cardiovascular Specialists
Baltimore, Maryland
Massachusetts General Hospital
Boston, Massachusetts
Onyx Clinical Research
Flint, Michigan
Onyx Clinical Research
Rochester Hills, Michigan
Stern Cardiovascular
Southaven, Mississippi
NYU Langone Hospital - Long Island
Mineola, New York
Orchard Park Family Practice
Orchard Park, New York
Clinical Trials of America, LLC
Lenoir, North Carolina
Diabetes and Endocrinology Consultants, P.C.
Morehead City, North Carolina
OnSite Clinical Solutions, LLC
Salisbury, North Carolina
The Ohio State University (OSU)
Columbus, Ohio
SV Research LLC
Marion, Ohio
Oklahoma Heart Institute
Tulsa, Oklahoma
Showing 40 of 205 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.